TITLE

AASTROM BIOSCIENCES REPORTS POSITIVE HUMAN JAW BONE RESULTS

PUB. DATE
February 2006
SOURCE
Worldwide Biotech;Feb2006, Vol. 18 Issue 2, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the results of a feasibility clinical trial, conducted by Ann Arbor, Michigan-based Aastrom Biosciences Inc., on the use of its Tissue Repair Cells (TRC) for maxillary bone reconstruction. Clinical safety; Web site where the results of the clinical trial may be accessed; Clinical information on TRC.
ACCESSION #
20451864

 

Related Articles

  • Aastrom gets grant to study bone-grafting technique. Bailey, Laura // Crain's Detroit Business;7/7/2003, Vol. 19 Issue 27, p4 

    Aastrom Biosciences Inc. announced Thursday that it has received a Small Business Innovation Research Phase I grant to fund development of stem-cell-based approaches to regenerate bone in bone-graft patients. This is the third such grant awarded to Aastrom by the National Institutes of Health...

  • When a cell is a `buy' Bridgeforth, Arthur // Crain's Detroit Business;10/06/97, Vol. 13 Issue 40, p2 

    Looks at Aastrom Biosciences Incorporated's stock, with reference to clinical trials which were approved by the United States Food and Drug Administration. Details on Aastrom using cells from spent umbilical cords to aid in the treatment of cancer; Comments from president of Aastrom, R. Douglas...

  • Clinic Roundup.  // BioWorld Today;5/31/2011, Vol. 22 Issue 104, p5 

    This section offers news briefs related to clinical trials including a collaboration formed between Aastrom Biosciences Inc. and CPC Clinical Research to provide services related to an Aastrom trial of ixmyelocel-T and the positive data reported by UCB SA on a study of Cimzia as an additional...

  • Aastrom heart stem cell trial on hold after adverse event. HOLLINGSWORTH, CATHERINE // Medical Device Daily;2/4/2009, Vol. 13 Issue 22, p2 

    This article reports on the results of the U.S. Phase II heart failure trial conducted by Aastrom Biosciences. The company said that a patient enrolled in the trial developed a serious adverse event associated with anesthesia management during treatment at one of the study sites. It suspended...

  • Pharma Developments.  // Cardiovascular Devices & Drugs;Dec2008, Vol. 14 Issue 12, p18 

    The article reports on the treatment of the 30th patient by Aastrom Biosciences under its Phase IIb RESTORE-CLI trial. This marked the initial step toward interim data retrieval from the said study. The said study evaluated the function of Vascular Repair Cells (VRC) in the treatment of critical...

  • Aastrom adds another hospital to bone-grafting trials. Dietderich, Andrew // Crain's Detroit Business;2/28/2005, Vol. 21 Issue 9, p18 

    This article reports that Ann Arbor, Michigan-based Aastrom Biosciences Inc. has added Lutheran Medical Center in New York City to its list of hospitals and medical centers participating in clinical trials of its bone-grafting treatment. Aastrom already is conducting trials at Lutheran General...

  • Aastrom Raises $13.5M For Regenerative Products.  // BioWorld Today;10/17/2007, Vol. 18 Issue 202, p7 

    The article reports that Aastrom Biosciences Inc. entered into agreements to raise capital for its regenerative stem cell products. With its Phase III clinical trials under way for the treatment of osteonecrosis of the femoral head, the company will sell its stocks through registered direct...

  • CLINIC ROUNDUP.  // BioWorld Today;10/5/2007, Vol. 18 Issue 194, p6 

    This section offers news briefs related to clinical trials in the U.S. Aastrom Biosciences Inc. in Ann Arbor, Michigan reported positive interim results from studies on the use of autologous stem cell products manufactured with its Tissue Repair Cell technology platform. Gilead Sciences Inc. in...

  • CLINIC ROUNDUP.  // BioWorld Today;11/24/2008, Vol. 19 Issue 229, p4 

    This section offers news briefs on biotechnological research in the U.S. as of Novemver 24, 2008. Aastrom Biosciences Inc. said the first patient was treated in its Phase II IMPACT-DCM trial designed to evaluate the company's Cardiac Repair Cells in dilated cardiomyopathy. Epeius Biotechnologies...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics